Articles
This is the second article in a 4-part series on bendamustine. This article discusses the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling Read More ›
The 2015 Annual Congress of the Oncology Nursing Society (ONS) marks the 40th anniversary of the organization. Presentations and events included the tried and true and the new. Read More ›
The United States lags behind other developed countries in uptake of the human papillomavirus (HPV) vaccine, and nurses and other healthcare providers can improve the situation. Read More ›
Handling and disposing of oral cancer therapies can be hazardous, and certain protocols should be followed to reduce risks, according to Lisa Holle, PharmD, who spoke at the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference. Read More ›
At the American Society for Blood and Marrow Transplantation’s (ASBMT) 2015 BMT Tandem Meetings, 4 studies were named the “Best Pharmacy Abstracts,” and are summarized here for our readers. Read More ›
The American Society for Blood and Marrow Transplantation (ASBMT) Pharmacy Special Interest Group (SIG) is rapidly growing in both membership and opportunities, according to Jamie F. Shapiro, PharmD, BCOP, Clinical Pharmacy Coordinator, Stem Cell Transplant, and Chair of the ASBMT Pharmacy SIG. Read More ›
By Chase Doyle
According to a recent assessment of bowel dysfunction–related needs, the hardships for colorectal cancer (CRC) survivors continue long after leaving the operating room, and survivors desire more information and strategies to help cope with unexpected changes to their bowel patterns, researchers said at the 2015 Gastrointestinal Cancers Symposium held in San Francisco, CA. Read More ›
“There is a very strong link between shift work and lack of sleep, and fewer hours of sleep can translate to a higher risk for obesity and disease,” according to Eva S. Schernhammer, MD, DrPH, who spoke at the recent American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research. Read More ›
Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA. Read More ›